Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/26/2012US20120190003 Organ arrest, protection, preservation and recovery
07/26/2012US20120189724 Polyphenol-containing composition for oral administration or external use and use of same
07/26/2012US20120189720 Method for treatment of diarrhea-predominant irritable bowel syndrome
07/26/2012US20120189719 Schisandrae fructus extracts for inhibition or prevention of h1n1 influenza virus infection and its application thereof
07/26/2012US20120189717 Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting
07/26/2012US20120189716 Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting
07/26/2012US20120189715 Compositions including beta-hydroxy-beta-methylbutyrate and uses thereof
07/26/2012US20120189714 Compositions including beta-hydroxy-beta-methylbutyrate
07/26/2012US20120189713 Monomers and phase-separated biocompatible polymer compositions prepared therefrom for medical uses
07/26/2012US20120189711 Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases
07/26/2012US20120189710 Antibacterial compositions
07/26/2012US20120189709 Method of using beta-hydroxy-beta-methylbutyrate to treat a condition
07/26/2012US20120189706 Macrocystis Pyrifera Derived Health and Wellness Products and Methods of Using the Same
07/26/2012US20120189705 Pharmaceutical Compositions
07/26/2012US20120189699 Polysaccharide gel formulation having multi-stage bioactive agent delivery
07/26/2012US20120189698 Pharmaceutical Dosage Forms for the Release of Active Compounds
07/26/2012US20120189697 Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
07/26/2012US20120189696 Coating film, and granules and tablets each utilizing same
07/26/2012US20120189695 Pharmaceutical dosage form
07/26/2012US20120189694 Co-precipitate comprising a phosphodiesterase-5 inhibitor (pde-5-inhibitor) and a pharmaceutically compatible carrier, production and use thereof
07/26/2012US20120189693 Oral dosage forms
07/26/2012US20120189692 Pharmaceutical Compositions of Iron for Oral Administration
07/26/2012US20120189691 Drug carrier and drug carrier kit for inhibiting fibrosis
07/26/2012US20120189688 Carrier component and fabrication method thereof
07/26/2012US20120189686 Transdermal levonorgestrel device and delivery
07/26/2012US20120189684 Skincare Compositions
07/26/2012US20120189682 Inhibition of biofilm organisms
07/26/2012US20120189678 Liposome and Personal Care Composition Comprising Thereof
07/26/2012US20120189671 Absorbable Implants and Methods for their use in Hemostasis
07/26/2012US20120189670 Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
07/26/2012US20120189667 Method for repairing or replacing damaged tissue
07/26/2012US20120189666 Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
07/26/2012US20120189655 Attenuated Live Vaccine for Prevention of Porcine Reproductive and Respiratory Syndrome
07/26/2012US20120189653 Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient
07/26/2012US20120189646 Novel compounds
07/26/2012US20120189645 Compositions and methods to treat and control tumors
07/26/2012US20120189642 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
07/26/2012US20120189638 Method of treating neurodegenerative disease
07/26/2012US20120189623 Cyclized derivatives as eg-5 inhibitors
07/26/2012US20120189616 Isosorbide nitrates
07/26/2012US20120189615 CROSS-ß STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS-ß STRUCTURE, FOR MODULATING CROSS-ß STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS-ß STRUCTURE-MEDIATED TOXICITY
07/26/2012US20120189614 Inhibitors of filovirus entry into host cells
07/26/2012US20120189613 Stim2-mediated capacitive calcium entry
07/26/2012US20120189612 Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
07/26/2012US20120189607 Method of regulating fertilizing ability using cyclic adp-ribose and cd38
07/26/2012US20120189600 Compositions and methods for treating neurodegenerative diseases
07/26/2012US20120189597 Nutritional compositions including exogenous nucleotides
07/26/2012US20120189580 Anti-infective agents and uses thereof
07/26/2012US20120189579 Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
07/26/2012US20120189576 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
07/26/2012US20120189575 Oligodendrocyte Production from Multipotent Neural Stem Cells
07/26/2012US20120189574 Methods for hematopoietic precursor mobilization
07/26/2012US20120189571 Nanoscale platinum compounds and methods of use thereof
07/26/2012US20120189569 Hydroxy Acid Complexes for Skin Renovation and Clarity
07/26/2012US20120189568 Antimicrobial amino-salicylic acid derivatives
07/26/2012US20120189567 Artemisinin Derivatives with Natural Amino Acids, Peptides, and Amino Sugars for Skin Imperfections and Infection in Mammals
07/26/2012US20120189566 External preparation containing pantethine phosphate ester
07/26/2012US20120189565 Skin clarifying complex, use of said complex, cosmestic or pharmaceutical composition comprising said complex and method for application thereof
07/26/2012US20120189563 Oral composition for alleviating ultraviolet irradiation-induced damage
07/26/2012US20120189556 Pharmaceutical compositions based on anticholinergics and corticosteroids
07/26/2012US20120189555 Methods and compositions for prevention or treatment of rsv infection
07/26/2012US20120189550 Orally administered bacteria as vehicles for systematic delivery of agents
07/26/2012US20120189543 Compositions and Methods for Detecting and Treating Implant Loosening and Osteolysis
07/26/2012US20120189539 Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
07/26/2012US20120189538 Use of a2a adenosine receptor agonists
07/26/2012US20120189537 Nitrile derivatives and their pharmaceutical use and compositions
07/26/2012US20120189493 Anti-microbial systems and methods
07/26/2012DE102011009305A1 Medizinisches Präparat zur Behandlung der Zahnwurzel A medical preparation for the treatment of the tooth root
07/26/2012DE102010036997A1 LOV-Domänen Protein zur photosensiblen Desfunktionalisierung LOV domain protein for photosensitive Desfunktionalisierung
07/26/2012CA2828738A1 Fused aminodihydrothiazine derivatives useful as bace inhibitors
07/26/2012CA2825367A1 Diarylacetylene hydrazide containing tyrosine kinase inhibitors
07/26/2012CA2825308A1 Pyrazolopyrimidone compound for treating erectile dysfunction
07/26/2012CA2825124A1 Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
07/26/2012CA2825094A1 Pvrl4 (nectin 4) is a receptor for measles virus
07/26/2012CA2824996A1 Compounds and methods for enhancing hair growth
07/26/2012CA2824933A1 Pharmaceutical compositions and methods for making and using them
07/26/2012CA2824925A1 Quinazolinone inhibitors of dynein
07/26/2012CA2824900A1 Treatment of cognitive dysfunction in schizophrenia
07/26/2012CA2824873A1 Bicyclic carboxamide inhibitors of kinases
07/26/2012CA2824871A1 Bicyclic inhibitors of alk
07/26/2012CA2824808A1 Olefin containing nuclear transport modulators and uses thereof
07/26/2012CA2824646A1 FERRIC CITRATE CONTAINING SUBSTANTIALLY NO ß-OXIDIZED IRON HYDROXIDE
07/26/2012CA2824544A1 Picolinamide inhibitors of kinases
07/26/2012CA2824460A1 Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
07/26/2012CA2824437A1 Diazeniumdiolate derivatives
07/26/2012CA2824433A1 Aqueous liquid bromfenac composition having preservative efficacy
07/26/2012CA2824430A1 Orally dispersible tablet
07/26/2012CA2824352A1 Methods and compositions for treating kidney disorders
07/26/2012CA2824344A1 Mineralocorticoid receptor antagonists
07/26/2012CA2824332A1 Bicyclic inhibitors of alk
07/26/2012CA2824317A1 Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
07/26/2012CA2824316A1 Organic amine salts of azilsartan, preparation method and use thereof
07/26/2012CA2823955A1 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
07/26/2012CA2823780A1 Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer
07/26/2012CA2823705A1 Wound healing device and method
07/26/2012CA2823629A1 Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
07/26/2012CA2823622A1 Solid molecular dispersion of fesoterodine
07/26/2012CA2822540A1 Use of stathmin as a biomarker of drug response to furazanobenzimidazoles
07/26/2012CA2822530A1 Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
07/26/2012CA2822491A1 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
1 ... 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 ... 7860